Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20220928006
TCTR20220928006
Completed
Not Applicable

FLT3 Gene Mutations among Acute Myeloid Leukemia patients in Northeast Thailand

/A0 sites65 target enrollmentSeptember 28, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
/A
Enrollment
65
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Frequencies of FLT3-ITD and TKD were found to be 16.9% (11/65) and 10.8% (7/65), respectively. The WBC and peripheral blast percentage of FLT3-ITD positive patients were statistically significantly higher than those of the FLT3-wild type patients, while the peripheral blast percentage of FLT3-TKD positive patients was significantly lower. No other clinical characteristics among FLT3 positive and FLT3-wild type patients were observed.DNA sequencing identified 4 FLT3-TKD mutations.

Registry
who.int
Start Date
September 28, 2022
End Date
May 31, 2021
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
/A

Eligibility Criteria

Inclusion Criteria

  • •all newly diagnosed AML patients between January 2020 and May 2021

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid LeukemiaAcute Myeloid Leukemia
NCT01141673Taipei Medical University WanFang Hospital100
Active, not recruiting
Phase 3
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyAcute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
NCT04027309Stichting Hemato-Oncologie voor Volwassenen Nederland777
Recruiting
Phase 1
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 MutationFLT3 Gene MutationAML
NCT06561880Institute of Hematology & Blood Diseases Hospital, China36
Unknown
Not Applicable
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.Acute Myeloid Leukemia
NCT05383014Assiut University82
Recruiting
Not Applicable
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic TreatmentsMyeloid Leukemia, Acute
NCT06764459IRCCS Azienda Ospedaliero-Universitaria di Bologna20